Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991582 | 1.00 | ALDH1A1 (0.71) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 | |
| SCHEMBL12722331 | 0.85 | ALDH1A1 (0.77) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 | |
| SCHEMBL5315268 | 0.84 | ALDH1A1 (0.75) | ALDH1A1KDM4ECYP2C9CYP2C19CYP1A2 | |
| SCHEMBL14185243 | 0.84 | ALDH1A1 (0.75) | ALDH1A1KDM4ECYP2C19CYP1A2MAPT | |
| SCHEMBL13692850 | 0.84 | MAPT (0.80) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 | |
| SCHEMBL5266910 | 0.83 | ALDH1A1 (1.00) | ALDH1A1KDM4ECYP2C9CYP2C19CYP1A2 | |
| SCHEMBL2332295 | 0.82 | ALDH1A1 (0.76) | ALDH1A1KDM4ECYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5427914 | 0.82 | NPC1 (1.00) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 | |
| SCHEMBL3204569 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 | |
| SCHEMBL2948885 | 0.81 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| CN-212757256-U | Be applied to drying device that buchanania chinensis draws flavonoid composition | 赣南卫生健康职业学院 | 2021-03-23 | — | — | CN | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| US-6608089-B2 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2003-08-19 | — | — | US | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
| EP-1212312-B1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA SPA (IT) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | INDENA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
| CN-1371371-A | Novel derivatives of flavones, xanthones and coumarins | INDENA SPA (IT) | 2002-09-25 | — | — | CN | disclosed |
| EP-1212312-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017985-A1 | NOVEL DERIVATIVES OF FLAVONES, XANTHONES AND COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 350/4885KDM4E 4387/4885NPC1 3511/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 351/4885KDM4E 4387/4885NPC1 3546/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 350/4885KDM4E 4387/4885NPC1 3511/4885 |
| US-20020183318-A1 | Having antiproliferative activity and are useful as modulators of multiple drug resistance in cancer chemotherapy of neoplasms, for use in manufacture of medicament for menopausal disorders and osteoporosis | BRCA1, NCEH1, EZH1 | ALDH1A1 2996/4885KDM4E 2953/4885NPC1 29/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 986/4885KDM4E 1999/4885NPC1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.